Synopsis

Source of validity: Scientific
Rating (out of 5): 1

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been investigated for their potential neuroprotective properties in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. The rationale for their use is largely based on preclinical studies demonstrating that omega-3s may reduce neuroinflammation, oxidative stress, and neuronal apoptosis—processes implicated in ALS pathology. Animal studies, such as those using the SOD1 mutant mouse model of ALS, have shown that omega-3 supplementation can delay disease onset and modestly extend survival. However, results are inconsistent, with some studies finding no benefit or even potential harm at higher doses.

In humans, clinical evidence is extremely limited. Observational studies have suggested that higher dietary intake of omega-3s may be associated with a reduced risk of developing ALS, but these findings are not conclusive and do not address disease progression or treatment. No large, well-controlled clinical trials have established a clear benefit of omega-3 supplementation in ALS patients. As a result, leading ALS treatment guidelines do not recommend omega-3 fatty acids as a standard therapy for ALS. Therefore, while there is a scientific basis for investigating omega-3s in ALS, the evidence supporting their clinical use is weak, and their use remains experimental rather than standard practice.

More about omega-3 fatty acids
More about Lou Gehrig's Disease

Other ingredients used for Lou Gehrig's Disease

Other health conditions supported by omega-3 fatty acids

Products containing omega-3 fatty acids

Nature's Sunshine Flax Seed Oil (With Lignans)